This study aimed to assess the risk of hyperlactatemia (LA) in patients who received atorvastatin (ATV) treatment. An observational and retrospective study using a case-crossover study design. The participants who received atorvastatin (10 - 80 mg) were included in the sample. The main variable in the study was the total number of treatment days for all the medications administered to each patient (PD). All PDs with lactate>4mmol/L were cases, while all PDs with lactate≤4mmol/L were controls. The odds of ATV exposure were calculated for both cases and controls, and the odds ratio (OR) between cases and controls was also calculated.640 participants, aged of 87 years (±6), body mass index of 31.3 (±2.9) kg/m2 and 47% were female. The mean plasma lactate concentrations were 5.0±0.7mmol/L for the cases and 2.9±0.5mmol/L for the controls. Total PDs=5220, PDs with lactate≥4mmol/L=319; PDs with lactate<4 mmol/L=4901. OR=2.0 (95% CI: 1.52-2.63; Z4.97; P<0.0001): 73 out of 632 cases were exposed to ATV compared to 246 out of 4269controls. Likelihood of LA seems to be moderate (2≤OR<3, as per Cohen's standards).
